Segall Bryant & Hamill’s United Therapeutics UTHR Stock Holding History

Segall Bryant & Hamill’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,632	Closed	-$3.05M	–	736
2023 Q1	$3.05M	Buy	13,632 +12	+0.1%	+$2.96K	0.03%	395
2022 Q4	$3.79M	Sell	13,620 -4,859	-26%	-$1.23M	0.04%	363
2022 Q3	$3.87M	Buy	18,479 +975	+6%	+$218K	0.05%	351
2022 Q2	$4.12M	Sell	17,504 -3,992	-19%	-$812K	0.05%	350
2022 Q1	$3.86M	Sell	21,496 -2,342	-10%	-$446K	0.04%	366
2021 Q4	$5.15M	Buy	23,838 +570	+2%	+$112K	0.05%	320
2021 Q3	$4.3M	Buy	23,268 +931	+4%	+$183K	0.04%	360
2021 Q2	$4.01M	Buy	+22,337	New	+$4.25M	0.04%	366

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Segall Bryant & Hamill's UTHR Position: Q2 2023 in Review

Segall Bryant & Hamill sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 13,632 shares — an estimated $3.05M sold.

Segall Bryant & Hamill first reported a position in UTHR in Q2 2021 and held it in 8 quarters. The position peaked at $5.15M in Q4 2021. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Segall Bryant & Hamill reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 13,632 United Therapeutics shares in Q2 2023, an estimated $3.05M.
Segall Bryant & Hamill first reported a position in United Therapeutics in Q2 2021 and held it in 8 quarters.
Segall Bryant & Hamill's United Therapeutics position peaked at $5.15M in Q4 2021.
473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Segall Bryant & Hamill's 13F filing for Q2 2023, filed 14 Aug 2023.